{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:35Z","timestamp":1791920255662,"version":"4.3.4"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2019R1F1A1061677"],"award-info":[{"award-number":["2019R1F1A1061677"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["E0164503-02"],"award-info":[{"award-number":["E0164503-02"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ezetimibe, which lowers cholesterol by blocking the intestinal cholesterol transporter Niemann-Pick C1 like 1, is reported to reduce hepatic steatosis in humans and animals. Here, we demonstrate the changes in hepatic metabolites and lipids and explain the underlying mechanism of ezetimibe in hepatic steatosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We fed Otsuka Long-Evans Tokushima Fatty (OLETF) rats a high-fat diet (60\u00a0kcal % fat) with or vehicle (control) or ezetimibe (10\u00a0mg\u00a0kg<jats:sup>-1<\/jats:sup>) via stomach gavage for 12 weeks and performed comprehensive metabolomic and lipidomic profiling of liver tissue. We used rat liver tissues, HepG2 hepatoma cell lines, and siRNA to explore the underlying mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In OLETF rats on a high-fat diet, ezetimibe showed improvements in metabolic parameters and reduction in hepatic fat accumulation. The comprehensive metabolomic and lipidomic profiling revealed significant changes in phospholipids, particularly phosphatidylcholines (PC), and alterations in the fatty acyl-chain composition in hepatic PCs. Further analyses involving gene expression and triglyceride assessments in rat liver tissues, HepG2 hepatoma cell lines, and siRNA experiments unveiled that ezetimibe\u2019s mechanism involves the upregulation of key phospholipid biosynthesis genes, CTP:phosphocholine cytidylyltransferase alpha and phosphatidylethanolamine N-methyl-transferase, and the phospholipid remodeling gene lysophosphatidylcholine acyltransferase 3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrate that ezetimibe improves metabolic parameters and reduces hepatic fat accumulation by influencing the composition and levels of phospholipids, specifically phosphatidylcholines, and by upregulating genes related to phospholipid biosynthesis and remodeling. These findings provide valuable insights into the molecular pathways through which ezetimibe mitigates hepatic fat accumulation, emphasizing the role of phospholipid metabolism.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1406493","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:38:32Z","timestamp":1718599112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation"],"prefix":"10.3389","volume":"15","author":[{"given":"Hyekyung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ho","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyeon","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Gu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R26","DOI":"10.1152\/ajpregu.00049.2014","article-title":"Oxidative stress and altered lipid homeostasis in the programming of offspring fatty liver by maternal obesity","volume":"307","author":"Alfaradhi","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1139\/apnm-2012-0261","article-title":"Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine","volume":"38","author":"Arendt","year":"2013","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2013.05.030","article-title":"The metabolomic window into hepatobiliary disease","volume":"59","author":"Beyo\u011flu","year":"2013","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1038\/nutd.2016.12","article-title":"Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice","volume":"6","author":"Cash","year":"2016","journal-title":"Nutr. Diabetes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0206152","DOI":"10.1371\/journal.pone.0206152","article-title":"CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.metabol.2015.02.001","article-title":"Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK\/ERK pathway rather than dipeptidyl peptidase 4 inhibition","volume":"64","author":"Chang","year":"","journal-title":"Metabolism"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.3748\/wjg.v21.i25.7754","article-title":"Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats","volume":"21","author":"Chang","year":"","journal-title":"World J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1194\/jlr.M028902","article-title":"Lipidomic analysis of lipid droplets from murine hepatocytes reveals distinct signatures for nutritional stress","volume":"53","author":"Chitraju","year":"2012","journal-title":"J. Lipid Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/biomedicines8110512","article-title":"Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue","volume":"8","author":"Cho","year":"2020","journal-title":"Biomedicines"},{"key":"B12","first-page":"95","article-title":"Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells","volume":"2","author":"Cui","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"29683","DOI":"10.1074\/jbc.274.42.29683","article-title":"Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway","volume":"274","author":"Delong","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1016\/j.febslet.2007.11.023","article-title":"Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome","volume":"581","author":"Deushi","year":"2007","journal-title":"FEBS Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/dom.12749","article-title":"Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance","volume":"18","author":"Drouin-Chartier","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2013.11.001","article-title":"Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease","volume":"146","author":"Dumas","year":"2014","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1194\/jlr.M027599","article-title":"Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes","volume":"53","author":"Engelking","year":"2012","journal-title":"J. Lipid Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1074\/jbc.274.7.3970","article-title":"Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene","volume":"274","author":"Frohnert","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/s0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagn\u00e9","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nature06928","article-title":"Functional genomic screen reveals genes involved in lipid-droplet formation and utilization","volume":"453","author":"Guo","year":"2008","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e06328","DOI":"10.7554\/eLife.06328","article-title":"Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport","volume":"4","author":"Hashidate-Yoshida","year":"2015","journal-title":"Elife"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1194\/jlr.M900058-JLR200","article-title":"L-FABP directly interacts with PPARalpha in cultured primary hepatocytes","volume":"50","author":"Hostetler","year":"2009","journal-title":"J. Lipid Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"47402","DOI":"10.1074\/jbc.M404027200","article-title":"Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins","volume":"279","author":"Jacobs","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3898502","DOI":"10.1155\/2016\/3898502","article-title":"Metabolomics and type 2 diabetes: translating basic research into clinical application","volume":"2016","author":"Klein","year":"2016","journal-title":"J. Diabetes Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cmet.2011.07.013","article-title":"Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase","volume":"14","author":"Krahmer","year":"2011","journal-title":"Cell Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.pharep.2014.03.006","article-title":"The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia","volume":"66","author":"Krysiak","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/hep.24782","article-title":"Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice","volume":"55","author":"Ling","year":"2012","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cmet.2006.03.007","article-title":"The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis","volume":"3","author":"Li","year":"2006","journal-title":"Cell Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","article-title":"Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Musso","year":"2009","journal-title":"Prog. Lipid Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"G1043","DOI":"10.1152\/ajpgi.00250.2011","article-title":"Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance","volume":"302","author":"Naples","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B36","volume-title":"Guide for the Care and use of laboratory animals","year":"1996"},{"key":"B37","doi-asserted-by":"publisher","first-page":"797923","DOI":"10.3389\/fphar.2022.797923","article-title":"Regression of liver steatosis following phosphatidylcholine administration: a review of molecular and metabolic pathways involved","volume":"13","author":"Osipova","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1083\/jcb.201803153","article-title":"Lipid droplet size directs lipolysis and lipophagy catabolism in hepatocytes","volume":"218","author":"Schott","year":"2019","journal-title":"J. Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"44507","DOI":"10.1074\/jbc.M207712200","article-title":"The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition","volume":"277","author":"Tauchi-Sato","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1172\/JCI30060","article-title":"Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe","volume":"117","author":"Temel","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.abb.2014.05.013","article-title":"Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis","author":"Terashima","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"B46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/HEP.0000000000000375","article-title":"Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis","volume":"79","author":"Tian","year":"2024","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12944-019-1179-0","article-title":"Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"Van Der Veen","year":"","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1194\/jlr.M070631","article-title":"Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase","volume":"58","author":"Van Der Veen","year":"","journal-title":"J. Lipid Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-physiol-020518-114444","article-title":"Phospholipid remodeling in physiology and disease","volume":"81","author":"Wang","year":"2019","journal-title":"Annu. Rev. Physiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e57165","DOI":"10.1371\/journal.pone.0057165","article-title":"Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis","volume":"8","author":"Wattacheril","year":"2013","journal-title":"PLoS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.26930","article-title":"Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant \u03b11-antitrypsin Z deposition","volume":"59","author":"Yamamura","year":"2014","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbrc.2011.02.129","article-title":"Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes","volume":"407","author":"Yang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1111\/bph.14434","article-title":"Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes","volume":"175","author":"Yang","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","article-title":"Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study","volume":"40","author":"Yoneda","year":"2010","journal-title":"Hepatol. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1406493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:38:39Z","timestamp":1718599119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1406493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":56,"alternative-id":["10.3389\/fphar.2024.1406493"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1406493","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"article-number":"1406493"}}